Immunotherapy and radiation for advanced throat cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests combining induction chemotherapy and immunotherapy with radiation, with or without additional chemotherapy, for patients with advanced nasopharyngeal cancer (throat cancer). It aims to see if adding chemotherapy during radiation improves outcomes compared to not having it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a certain type of nasopharyngeal cancer (throat cancer) that has not spread to other parts of the body.
- Your cancer stage must be Stage III or IVa (but not a specific substage like T3N0M0).
- Your general health should be good enough to perform daily activities (Karnofsky score of at least 70).
- Your blood counts need to be within acceptable ranges (white blood cells, red blood cells, and platelets).
- Your liver and kidney function should be adequate, based on blood tests.
- You must not have had prior chemotherapy, radiation therapy, or surgery (beyond biopsy) for this cancer, and you must not have other cancers (with some exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This Phase 3 trial tests giving chemotherapy first, then either radiation alone or chemotherapy together with radiation. It aims to improve treatment control for people with newly diagnosed, advanced nasopharyngeal cancer.
This trial tests whether adding chemotherapy before the usual radiation and chemotherapy treatment can improve outcomes for people with a certain type of nasopharyngeal cancer that has higher risk features. It aims to see if the extra treatment helps control the cancer better.
This Phase 3 trial compares giving radiation alone versus giving radiation at the same time as chemotherapy for nasopharyngeal cancer. It focuses on people whose EBV test becomes undetectable after one cycle of chemotherapy, to see which approach works best and is safest.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.